Destiny Pharma targets growth as anti-infection treatments return to prominence


() said its partner in China is to launch a new programme aimed at delivering a new product using Destiny’s XF-73 to target the prevention and treatment of superficial skin infections caused by bacteria.

() Ltd (CMS), the AIM-listed company’s regional partner and also an investor with a 5.76% stake, is establishing a programme in China to focus on developing a novel product in the local regulatory environment.

CMS will lead, manage and fund the programme, with Destiny contributing scientific advice as required through a steering committee to the expert dermatology team at CMS.

Destiny Pharma noted that CMS already has a portfolio of dermatology assets and therefore an expert understanding of the market and its requirements through its existing sales and marketing infrastructure.


Please enter your comment!
Please enter your name here